Protalix 10-Q: $26.1M Nine-Month Profit, $48.5M Cash, No Debt
PLX sits 56% above its 52-week low of $1.65.
Summary
Protalix's Q3 10-Q shows nine-month net income of $26.1M (boosted by a $25.0M Chiesi milestone), $48.5M of cash and deposits with no debt, and continued modest ATM selling — 1.6M shares for $4.3M in Q3 plus 1.8M shares for $4.9M after quarter-end.
Key Events · Earnings and Guidance · PLX
-
Nine-Month Profit of $26.1M
Net income was $26,055K for the nine months ended September 30, 2026 versus a $(1,100)K loss a year earlier; Q3 alone earned $3,961K ($0.05 per diluted share) on $21,925K of revenue.
-
Revenue Jump on Chiesi Milestone
Nine-month revenue reached $75,571K versus $43,622K, including $26,490K of license and R&D revenue that contains the $25.0M E4W-dosage milestone received March 31, 2026.
-
$48.5M Cash, No Debt
Cash and cash equivalents of $22,035K plus short-term bank deposits of $26,503K totaled $48.5M at September 30, 2026; management states this funds at least 12 months of operations.
-
ATM Still Dripping Shares
1,613,992 shares were sold under the Sales Agreement in Q3 for ~$4.3M gross ($0.1M costs), and a further 1,798,325 shares for ~$4.9M gross after quarter-end; ~$11.3M remains available.
Analysis · PLX · Life Sciences
The 10-Q puts hard numbers behind this morning's 8-K headline. Nine-month net income of $26.1M versus a $1.1M loss a year ago is driven largely by the one-time $25.0M Chiesi milestone booked in Q1, so the underlying run-rate is thinner than the headline: Q3 alone earned $4.0M on $21.9M of revenue. The balance sheet is the real story — $48.5M in cash and short-term deposits with no debt and no warrants, which management says funds at least 12 months of operations. Against that, the company is still drip-selling stock: 1.6M shares for $4.3M in Q3 and another 1.8M shares for $4.9M after quarter-end, leaving $11.3M on the ATM. R&D spend rose 55% in Q3 to $6.9M as the PRX-115 gout study ramps, partly offset by a $1.0M Israeli R&D grant.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLX was trading at $2.58 on NYSE in the Life Sciences sector, with a market capitalization of approximately $207.1M. The 52-week trading range was $1.65 to $3.19. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.